Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Birrer

Showing results (81-90 of 222) with videos related to

Pageof 23
Sort By:
Molecular Cancer Therapeutics|September 19, 2007
Reactive oxygen species mediated apoptosis of esophageal cancer cells induced by marine triprenyl toluquinones and toluhydroquinonesCatherine E Whibley, Kerry L McPhail, Robert A Keyzers, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 7, 2011
ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approachesHua Li, Benjamin G Bitler, Vinod Vathipadiekal, et al.
Gynecologic Oncology Reports|August 31, 2019
Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancerElizabeth K Lee, Zhenying Tan-Wasielewski, Ursula A Matulonis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancerKristin K Zorn, Tomas Bonome, Lisa Gangi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomasMichael J Birrer, Michael E Johnson, Ke Hao, et al.
Journal of the National Cancer Institute|April 5, 2014
Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samplesMarkus Riester, Wei Wei, Levi Waldron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2019
Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic CancerTsz-Lun Yeung, Cecilia S Leung, Kay-Pong Yip, et al.
Cancer Research|August 6, 2011
Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescenceBenjamin G Bitler, Jasmine P Nicodemus, Hua Li, et al.
Journal of the National Cancer Institute|October 24, 2017
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker AnalysesCarlos Bais, Barbara Mueller, Mark F Brady, et al.
Cancer Research|September 5, 2006
Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancerJan S Sunde, Howard Donninger, Kongming Wu, et al.
Pageof 23

Showing results (81-90 of 222) with videos related to

Sort By:
Pageof 23
Molecular Cancer Therapeutics|September 19, 2007
Reactive oxygen species mediated apoptosis of esophageal cancer cells induced by marine triprenyl toluquinones and toluhydroquinonesCatherine E Whibley, Kerry L McPhail, Robert A Keyzers, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 7, 2011
ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approachesHua Li, Benjamin G Bitler, Vinod Vathipadiekal, et al.
Gynecologic Oncology Reports|August 31, 2019
Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancerElizabeth K Lee, Zhenying Tan-Wasielewski, Ursula A Matulonis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancerKristin K Zorn, Tomas Bonome, Lisa Gangi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomasMichael J Birrer, Michael E Johnson, Ke Hao, et al.
Journal of the National Cancer Institute|April 5, 2014
Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samplesMarkus Riester, Wei Wei, Levi Waldron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2019
Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic CancerTsz-Lun Yeung, Cecilia S Leung, Kay-Pong Yip, et al.
Cancer Research|August 6, 2011
Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescenceBenjamin G Bitler, Jasmine P Nicodemus, Hua Li, et al.
Journal of the National Cancer Institute|October 24, 2017
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker AnalysesCarlos Bais, Barbara Mueller, Mark F Brady, et al.
Cancer Research|September 5, 2006
Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancerJan S Sunde, Howard Donninger, Kongming Wu, et al.
Pageof 23